Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient

摘要

>Background style="font-family:Verdana;">>: Agent targeting HER-2 pathway plus chemotherapy has style="font-family:Verdana;"> represented a major progress in the management of patients with breast cancer. However style="font-family:Verdana;">, style="font-family:Verdana;"> the role of late-line treatment in heavily pretreated patients is still largely unclear. In the last decade style="font-family:Verdana;">, style="font-family:;" "=""> style="font-family:Verdana;"> nab-paclitaxel has shown significant activity and good toxicity profile in metastatic breast cancer. style="font-family:Verdana;">Case Presentation style="font-family:Verdana;">: style="font-family:;" "=""> style="font-family:Verdana;">We report the case of a 76-year-old Caucasian woman with metastatic HER-2 positive ductal infiltrating breast carcinoma treated with a combination of weekly nab-paclitaxel and trastuzumab as fifth-line therapy. She had previously received first-line paclitaxel and trastuzumab, second-line vinorelbine and trastuzumab, third-line TDM1 and fourth-line oral capecitabine and lapatinib. Clinical and radiological staging showed progression at bone, skin and soft-tissue. The patient received weekly nab-paclitaxel plus trastuzumab. Massive objective response was clinically and PET documented which lasted 8 months. Tolerance to treatment was fairly good as well as cardiac safety. style="font-family:Verdana;">Conclusion style="font-family:Verdana;">: To the best of our knowledge, this is the first reported case of efficacy of nab-paclitaxel in combination with trastuzumab as fifth-line of treatment in a patient with metastatic HER-2 positive breast cancer.